Table 3.
Demographic characteristics for placebo and treated patients of the subset.
| Characteristics | Placebo + MTX (n = 11) | Tocilizumab 8 mg/kg (n = 23) | p value |
|---|---|---|---|
| Age | 53.4 (20–72) | 54.9 (20 – 76) | 0.779 |
| Gender, % female | 81.8% | 95.5% | 0.252 |
| Ethnicity |
72.7% Non-Hispanic 27.3% Hispanic |
90.9% Non-Hispanic 9.1% Hispanic |
0.304 |
| Race | 100% White |
95.5% White 4.5% Other |
0.999 |
| CRP | 4.339 (0.581–24.100) | 2.623 (0.113–12.500) | 0.299 |
| ESR | 51.73 (17–186) | 45.64 (8–118) | 0.780 |
| HAQ | 1.750 (0.375–3.000) | 1.517 (0.375–2.750) | 0.274 |
| SJC | 18.09 (7–39) | 18.14 (7–36) | 0.858 |
| TJC | 28.18 (9–46) | 31.73 (8–66) | 0.456 |
| VAS PAIN | 58.72 (29–79) | 63 (21–98) | 0.645 |
| DAS | 6.649 (4.441–7.702) | 6.804 (5.458–8.668) | 0.873 |
Categorical variables are described as percentages, while continuous variables as means (range) and were compared between the two groups (placebo and treated) with Mann–Whitney test. P values are shown in the last column. Statistical significance is considered as *P < 0.05, ns = P > 0.05. CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, HAQ: health assessment questionnaire, SJC: swollen joint count, TJC: tender joint count, VAS: visual analogue scale, DAS: disease activity score.